Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 1. The Expression of SELENBP1 in Normal and Tumor Breast Tissues. Breast cancer tissue arrays were stained by immunohistochemistry using anti-human SELENBP1 antibody at 1:100 dilution. Positive stained cells are shown in dark brown color. (A) Strong positive staining of SELENBP1 in normal breast tissue under low power view (200X). (B–C) Weak positive to negative staining of SELENBP1 in breast cancer tissues under high power view (400X). (D) The Allred scoring distributions of SELENBP1 expression in normal and tumor tissue groups. Inside lines represent means and standard deviations. *p,0.05. (E) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. doi:10.1371/journal.pone.0063702.g001

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing, Staining, Immunohistochemistry, Negative Staining

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 2. SELENBP1 Expression is Progressively Reduced in Advancing Clinical Stages in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues at stage II and stage III. Inside lines represent means and standard deviations. **p,0.01. (B) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. (C) Survival curves of breast cancer patients with respect to different SELENBP1 expression levels are shown at stage II and (D) stage III. Blue and red lines represent the SELENBP1-high and SELENBP1-low groups, respectively. doi:10.1371/journal.pone.0063702.g002

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 3. The Correlation of SELENBP1 Expression with ER, PR, and TP53 in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues with ER+ and ER– status. The inside lines represent means and standard deviations. **p,0.01. The difference between normal and ER+ and ER– tumor tissues was analyzed by Kruskal-Wallis test and statistical results are shown (B). Survival curves of breast cancer patients with respect to different SELENBP1 expression are shown in ER+ group in (C). The blue line is the SELENBP1- high group and the red line is the SELENBP1-low group. The scoring distributions of SELENBP1 expression in normal and tumor tissues with PR+/PR–

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: Cancer Science

Article Title: Design and Evaluation of Eb 4 Mab ‐7‐ mG 2a : A Dual‐Action Anti‐ EphB4 Monoclonal Antibody for Targeted Breast Cancer Therapy

doi: 10.1111/cas.70198

Figure Lengend Snippet: Prognostic significance of EphB4 expression in breast cancer and establishment of Eb 4 Mab‐7‐mG 2a . (A) Kaplan–Meier survival analysis of OS in breast cancer patients based on the expression levels of EphB family genes (EphB1, EphB2, EphB3, EphB4, and EphB6) using RNA‐seq data from KMplot. Among these genes, high expression of EphB2 and EphB4 was significantly associated with poor prognosis (log‐rank p < 0.05). Patients were then stratified into high and low expression groups using the optimal cutoff within the interquartile range. (B) Generation of a mouse IgG 2a version of the anti‐EphB4 monoclonal antibody (Eb 4 Mab‐7‐mG 2a ). The V H and V L regions of B4Mab‐7 (mouse IgG 1 ) were cloned into expression vectors containing mouse IgG 2a C H and C L regions. These vectors were transfected into BINDS‐09 cells to produce Eb 4 Mab‐7‐mG 2a . (C) Left: Expression of EphB4 and β‐Actin in CHO‐K1, CHO/EphB4, MCF‐7, and EphB4‐KO MCF‐7 cells. Right: Expression of EphB4 and GAPDH in normal human adult breast tissues, MCF10A (non‐tumorigenic mammary epithelial cells), MCF‐7, BT‐474, SK‐BR‐3, MDA‐MB‐468, and HBC5 cells.

Article Snippet: Aside from cell lysates, a commercially available normal human breast tissue lysate (Total Protein–Human Adult Normal Tissue: Breast, Novus Biologicals, Littleton, CO, USA) was used to assess expression in normal breast tissue.

Techniques: Expressing, RNA Sequencing, Clone Assay, Transfection